The clock appears to be ticking for GlaxoSmithKline PLC on the time it has left to enjoy exclusivity on its blockbuster asthma medication Advair Diskus in the US, but CEO Andrew Witty insisted during the company’s fourth quarter and year-end financial call Feb. 3 that GSK’s five-year outlook is not contingent on the timing of a generic launch.
Advair Generic Looms, But GSK Says Growth Will Return Regardless
CEO Andrew Witty reconfirmed that GSK’s respiratory business will return to growth in 2016 and said the company’s five-year outlook does not depend on the timing of a generic Advair. Mylan recently filed what is believed to be the first ANDA for a generic Advair Diskus in the US.